Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab

K. Muylle, P. Flamen, D. Vugts, T. Guiot, G. Ghanem, N. Meuleman, P. Bourgeois, B. Vanderlinden, G.A.M.S. van Dongen, H. Everaert, M. Vaes, D. Bron

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1304-1314
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number8
Publication statusPublished - 2015

Cite this